NGX267
Identification
- Generic Name
- NGX267
- DrugBank Accession Number
- DB05152
- Background
NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 214.33
Monoisotopic: 214.113984382 - Chemical Formula
- C10H18N2OS
- Synonyms
- Not Available
- External IDs
- AF-267B
- AF267B
- NGX-267
- NGX267
Pharmacology
- Indication
Investigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Due to its mechanism of action, NGX267 may be simultaneously effective in treating the memory and cognitive disturbances experienced by Alzheimer's patients and in reducing the creation of neurotoxic proteins, thereby delaying disease progression.
- Mechanism of action
NGX267 has been shown to stimulate M1 receptors in a fashion analogous to acetylcholine, a neurotransmitter essential for memory and cognitive function that is depleted when neurons, or brain cells, degenerate. The M1 receptor plays an important role in memory and cognitive processing. Its activation has also been linked to decreases in two biochemical processes, AB production and tau protein phosphorylation, both of which are involved in the creation of the neurofibrillary tangles and amyloidplaques that are major histopathological hallmarks of Alzheimer's disease. By selectively enhancing M1 cholinergic neurotransmission in the brain, NGX267 may offer advantages over current therapies for Alzheimer's disease due to the relative preservation of this system in patients who are clinically symptomatic.
Target Actions Organism UMuscarinic acetylcholine receptor M1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with NGX267. Ambenonium The risk or severity of adverse effects can be increased when Ambenonium is combined with NGX267. Amikacin The therapeutic efficacy of NGX267 can be decreased when used in combination with Amikacin. Aprotinin The risk or severity of adverse effects can be increased when Aprotinin is combined with NGX267. Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with NGX267. Betaine The risk or severity of adverse effects can be increased when Betaine is combined with NGX267. Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with NGX267. Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with NGX267. Capreomycin The therapeutic efficacy of NGX267 can be decreased when used in combination with Capreomycin. Capsaicin The risk or severity of adverse effects can be increased when Capsaicin is combined with NGX267. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8D3PZX7G73
- CAS number
- 503431-81-0
- InChI Key
- PHOZOHFUXHPOCK-QMMMGPOBSA-N
- InChI
- InChI=1S/C10H18N2OS/c1-3-8-9(13)11-10(14-8)4-6-12(2)7-5-10/h8H,3-7H2,1-2H3,(H,11,13)/t8-/m0/s1
- IUPAC Name
- (2S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one
- SMILES
- CC[C@@H]1SC2(CCN(C)CC2)NC1=O
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347909984
- ChemSpider
- 8189078
- ZINC
- ZINC000013816318
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Dry Mouth / Sjogren's Syndrome (SS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 13.5 mg/mL ALOGPS logP 1.21 ALOGPS logP 1.36 Chemaxon logS -1.2 ALOGPS pKa (Strongest Acidic) 11.85 Chemaxon pKa (Strongest Basic) 8.35 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 32.34 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 58.84 m3·mol-1 Chemaxon Polarizability 23.65 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets

- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52